Arix Bioscience Plc’s (LON:ARIX) investee company Aura Biosciences has reported positive results from the phase Ib/II clinical trial of its AU-011 eye cancer injection.
AU-011 is made up of viral nanoparticles which latch onto and, once activated by an ophthalmic laser, kill cancer cells in the back of the eye.
READ: Arix boosted by LogicBio's Nasdaq IPO
Importantly, they do this without damaging the surrounding tissue, preserving patients’ vision.
Brian Marr, the trial’s principal investigator, said: “These 12-month data demonstrate that light-activated AU-011 continues to be well-tolerated, including with multiple administrations, has evidence of tumour control and preservation of visual acuity”
Arix chief investment officer Joe Anderson added: “We believe that this minimally invasive, non-radiation-based treatment option, has the potential to offer a new treatment option for patients.”
“We continue to support Aura as the company progresses towards a pivotal phase III study.”
Arix, which has a 6.6% stake in Aura, saw its shares drop 4.1% to 162.6p in late-afternoon trading.